{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/005/SRR8956365/SRR8956365.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/007/SRR8956367/SRR8956367.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/003/SRR8956363/SRR8956363.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/004/SRR8956374/SRR8956374.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/003/SRR8956373/SRR8956373.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/000/SRR8956360/SRR8956360.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/008/SRR8956368/SRR8956368.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/001/SRR8956371/SRR8956371.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/004/SRR8956364/SRR8956364.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/006/SRR8956366/SRR8956366.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/002/SRR8956362/SRR8956362.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/000/SRR8956370/SRR8956370.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/001/SRR8956361/SRR8956361.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/002/SRR8956372/SRR8956372.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR895/009/SRR8956369/SRR8956369.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["MPI for heart and lung research"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA535500"],"scientific_name":["Mus musculus"],"tag":["xref:PubMed:31597643"],"long_description":["Glioblastoma multiforme (GBM) is a non T cell-inflamed cancer characterized by an immunosuppressive microenvironment that impedes dendritic cell maturation and T cell cytotoxicity. The alleviation of immunosuppression might be a prerequisite for succesful immune checkpoint therapy in GBM. We here combine anti-angiogenic and immune checkpoint therapy and demonstrate improved therapeutic efficacy in syngeneic, orthotopic GBM models. We observed that blockade of vascular endothelial growth factor (VEGF), Angiopoietin-2 (Ang-2) and programmed cell death protein-1 (PD-1) significantly extended survival compared to vascular targeting alone. In the GBM microenvironment, triple therapy increased the numbers of cytotoxic T-lymphocytes that inversely correlated with myeloid-derived suppressor and regulatory T cells. Furthermore, transcriptomic analysis of GBM microvessels indicates a global vascular normalization that was highest after triple therapy. Our results propose a rationale to overcome limitations of VEGF monotherapy by integrating the synergistic effects of VEGF/Ang-2 and PD-1 blockade to reinforce anti-tumor immunity through a normalized vasculature. Overall design: Brain microvessels were isolated from treated and untreated adult WT BL6/57 mice from tumor bearing brain region at 21 days post transplation followed by RNA sequecning. Three biological replicates were included for each group pooling 3 mice for each set. Contra-lateral brain region within each group and sham operated mice served as controls."],"repository":["ENA"],"description_synonyms":["Blood-Brain Barriers, Networks, Therapy, 3.4.22.-, BBB, grade IV adult astrocytic tumour, RNA, Hemato-Encephalic Barriers, Brain Blood Barrier, RNA Sequence Determination, Laboratory, RNA Sequence Determinations, Sequence Determination, RNA Sequence, Mus domesticus, mouse, mini-ICE, CASP-14, Network, Microvascular Network, House Mouse, Determinations, Brain-Blood, bbb, adult glioblastoma multiforme, disease management., Hemato Encephalic Barrier, House, Mus, primary glioblastoma multiforme, Mini-ICE, Mus musculus domesticus, Analysis, Mice, Hemato-Encephalic Barrier, Microvessel, glioblastoma multiforme, treatment, Mus musculus, Brain-Blood Barrier, grade IV adult astrocytic tumor, Caspase-14 subunit p10, Analyses, Barrier, Determination, Microvascular Networks, Swiss, spongioblastoma multiforme, mice, Swiss Mouse, GBM, House Mice, Swiss Mice, Caspase-14 subunit p19, MICE, Sequence Determinations, Treatments, Sequencing, Laboratory Mice, domesticus, Microvascular, Blood Brain Barrier, RNA Sequence Analyses, Therapeutic, grade IV adult Astrocytic tumor, RNA Sequence Analysis, Hemato-Encephalic, Brain-Blood Barriers, disease management, Therapies, RNA Sequencing, Blood-Brain, Treatment, Mouse, Barriers, blood-cerebral barrier, Microvasculature, Laboratory Mouse, Sequence Analyses"],"name_synonyms":["Blood-Brain Barriers, Networks, Therapy, 3.4.22.-, BBB, grade IV adult astrocytic tumour, RNA, Hemato-Encephalic Barriers, Brain Blood Barrier, RNA Sequence Determination, Laboratory, RNA Sequence Determinations, Sequence Determination, RNA Sequence, Mus domesticus, mouse, mini-ICE, CASP-14, Network, Microvascular Network, House Mouse, Determinations, Brain-Blood, bbb, adult glioblastoma multiforme, disease management., Hemato Encephalic Barrier, House, Mus, primary glioblastoma multiforme, Mini-ICE, Mus musculus domesticus, Analysis, Mice, Hemato-Encephalic Barrier, Microvessel, glioblastoma multiforme, treatment, Mus musculus, Brain-Blood Barrier, grade IV adult astrocytic tumor, Caspase-14 subunit p10, Analyses, Barrier, Determination, Microvascular Networks, Swiss, spongioblastoma multiforme, mice, Swiss Mouse, GBM, House Mice, Swiss Mice, Caspase-14 subunit p19, MICE, Sequence Determinations, Treatments, Sequencing, Laboratory Mice, domesticus, Microvascular, Blood Brain Barrier, RNA Sequence Analyses, Therapeutic, grade IV adult Astrocytic tumor, RNA Sequence Analysis, Hemato-Encephalic, Brain-Blood Barriers, disease management, Therapies, RNA Sequencing, Blood-Brain, Treatment, Mouse, Barriers, blood-cerebral barrier, Microvasculature, Laboratory Mouse, Sequence Analyses"],"additional_accession":[]},"is_claimable":false,"name":"RNA sequencing of blood-brain barrier (BBB) microvessels from mice with orthotopic GBM showing the benefit of triple therapy combining anti-immune checkpoint therapy with dual-anti angiogenic therapy.","description":"RNA sequencing of blood-brain barrier (BBB) microvessels from mice with orthotopic GBM showing the benefit of triple therapy combining anti-immune checkpoint therapy with dual-anti angiogenic therapy.","dates":{"last_updated":"2025-09-24","first_public":"2021-03-02"},"accession":"PRJNA535500","cross_references":{"GEO":["GSE130324"],"taxon":["10090"],"PubMed":["31597643"]}}